ClinicalTrials.gg
RecruitingNCT07097480SIMVIRUpdated Dec 15, 2025

Virus Transmission to People Recently Bitten or With a History of Monkey Bites "SIMVIR

An interventional study of Blood samples collection and Saliva samples collection in Bites Monkey, sponsored by Institut Pasteur. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Institut Pasteur · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 47 studies in Virus Diseases with a site in France — 9 open to participants now, 10 under way, 2 of them phase 3. Virus Diseases · France.

Planned enrollment
15th of 26
80 · median 113
Started
2025
with 3 others
No phase
10 of 47
3 open now
Registered
45th of 47
by date
Lead sponsor
2 of 47
Institut Pasteur

Among the 47 studies in Virus Diseases with a site in France, this one is the 15th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 45th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

9 of the 47 studies in Virus Diseases with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Virus Diseases with a site in France, or all of them as a file.
02

Study summary

Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.

The objective of the study is to investigate the prevalence of STLV-1 and SFV infections following a nonhuman primate bite.

Read the detailed description

Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.

Compared to other individuals exposed to nonhuman primates (NHPs), travelers have two unique characteristics. First, they are typically exposed only once to simian infectious agents, in contrast to the repeated exposure experienced by other at-risk groups. If exposure results in an infection event, travelers may spread these infectious agents to geographic areas where they do not normally circulate.

To address the following main objective: to study the prevalence of STLV-1 and SFV infections following a nonhuman primate bite. The study plans to include subjects who have been recently bitten as well as those with a history of nonhuman primate bites. Blood and saliva samples will be collected from the subjects.

03

Conditions studied

  • Bites Monkey

Keywords

  • Antirabies
  • Virus
  • Bite
  • Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Bite inflicted by an HNP (WHO category 3 level)
  • Written
  • Affiliation with a social security scheme (excluding State Medical Aid

Specific criteria for genetic analyses:

  • Participant has checked the boxes for participation in the genetic component.

Exclusion criteria

Exclusion Criteria:

  • Patient presenting only with scratches inflicted by a PNH
  • Medical management incompatible with the objectives of the study
  • Patient who, in the doctor's opinion, is unlikely to comply with the study protocol
  • Health conditions are incompatible with the sample collection required by the study
  • Patient under legal protection (guardianship or trusteeship)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Adults recently bitten by a non-human primate

    Adults recently bitten by a non-human primate and consulting at the Institut Pasteur medical center for prophylaxis as part of their care.

    Procedure: Blood samples collection · Procedure: Saliva samples collection

  • Other
    Adults with a history of bites

    Adults with a history of bites from a non-human primate who are consulting at the Institut Pasteur medical center as part of their routine care.

    Procedure: Blood samples collection · Procedure: Saliva samples collection

Interventions

  • ProcedureBlood samples collection

    Blood samples of 40 ml will be taken.

  • ProcedureSaliva samples collection

    Saliva samples will be collected

06

What researchers measure

Primary outcomes

  1. Study the prevalence of STLV-1 and SFV infections following an NHP bite.

    Detection of specific antibodies and viral DNA against both viruses in blood.

    Time frame: 17 months

Secondary outcomes

  1. Identify risk and demographic factors associated with STLV-1 and SFV infection.

    The study of associations between STLV-1 and SFV infection and demographic characteristics (age, sex) and those linked to the HNP bite (severity of injury, HNP species) will be analyzed by Fisher's exact test and the Mann-Withney test.

    Time frame: 17 months

Other outcomes

  1. Determine the kinetics of appearance of viral markers (viral DNA and antibodies) for each virus

    Measurement of viral markers (SFV RNA and DNA, STLV-1 DNA, virus-specific IgM and IgG) in blood and saliva.

    Time frame: 17 months

  2. Characterize detected STLV-1 and SFV viral strains

    Determination of complete viral sequences and integration sites in the human genome.

    Time frame: 17 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 61 interventional studies with no phase under Virus Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 16 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Jul 31, 2025
StartActual
Aug 14, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Aug 2028
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07097480
Lead sponsor
Institut Pasteur
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Aug 14, 2025
Primary completion
Dec 2026 (estimated)
Completion
Aug 2028 (estimated)
Last update
Dec 15, 2025

Study contacts

Florence BUSEYNE, PhD
Contact
florence.buseyne@pasteur.fr
0145688899 ext. +33
Patrick HOCHEDEZ, Dr
Contact
patrick.hochedez@pasteur.fr
0140669604 ext. +33
Patrick HOCHEDEZ, Dr
principal investigator · Institut Pasteur Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion